DR. GAURAV GARG

DR SUMEET LAHANE, Dr. SANTOSH G. HONAVAR, Dr.Sonal P Yadav

Abstract

PURPOSE: Efficacy and safety of Ru106 plaque brachytherapy in the treatment of OSSN with corneal stromal and scleral invasion.

METHODS: Retrospective interventional case series including 66 eyes of 66 patients, who underwent Ru-106 plaque brachytherapy. Tumor regression, eye salvage, vision salvage, and metastasis were the primary outcome measures.

RESULTS: Mean age at presentation was 50.5±15.0y. A mean dose of 5300±534 cGy was delivered over a mean duration of 22.0±9.6h. 30 (45%) underwent primary brachytherapy and 36 (55%) secondary. Mean follow-up was 36.2±16.7months. Tumor regression and eye salvage were noted in 58 (94%) eyes and 62 (94%) eyes respectively. Vision improved (>2 Snellen lines) or was stable in 50(81%). Cataract was noted in 6 eyes. None developed metastasis.

CONCLUSION: Ru-106 plaque brachytherapy provides gratifying outcome with impressive tumor control and eye and vision salvage in corneal stromal and scleral invasive OSSN.

Full Text